

In the Claims

1-62. (Canceled)

63. (Currently amended) A method of preventing or inhibiting an indication associated with a ~~chemokine-induced activity~~ leukocyte migration, comprising: administering to a mammal afflicted with, or at risk of, the indication an effective amount of Glu-Ile-Cys-Leu-Asp-Pro-Lys-Gln-Lys-Trp-Ile-Gln (SEQ ID NO:14).

64. (Previously presented) A method of preventing or inhibiting an indication associated with hematopoietic cell recruitment, comprising: administering to a mammal at risk of, or afflicted with, the indication an effective amount of Glu-Ile-Cys-Leu-Asp-Pro-Lys-Gln-Lys-Trp-Ile-Gln (SEQ ID NO:14).

65. (Currently amended) A method ~~to modulate the chemokine induced activity of preventing or inhibiting~~ hematopoietic ~~cells~~ cell recruitment at a preselected physiological site, comprising: administering to a mammal a dosage form comprising an effective amount of Glu-Ile-Cys-Leu-Asp-Pro-Lys-Gln-Lys-Trp-Ile-Gln (SEQ ID NO:14), wherein the dosage form is linked to a site targeting moiety.

66. (Canceled)

67. (Currently amended) A method of preventing or inhibiting an indication associated with a ~~chemokine-induced activity~~ leukocyte migration, comprising: administering to a mammal afflicted with, or at risk of, the indication an effective amount of a peptide comprising no more than 30 amino acid residues, which peptide comprises SEQ ID NO:1, SEQ ID NO:7, SEQ ID NO:38, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:65, SEQ ID NO:66, SEQ ID NO:67, SEQ ID NO:68, SEQ ID NO:72, SEQ ID NO:73, ~~or~~ SEQ ID NO:74, reverse D Glu-Ile-Cys-Leu-Asp-Pro-Lys-Gln-Lys-Trp-Ile-Gln, reverse D Glu-Ile-Cys-Leu-Asp-Pro-Lys-Gln-Lys-Trp-Ile-Gln-Cys, or reverse D Glu-Ile-Cys-Ala-Asp-Pro-Lys-Gln-Lys-Trp-Val-Gln-Cys.

68. (Currently amended) A method of preventing or inhibiting an indication associated with hematopoietic cell recruitment, comprising: administering to a mammal at risk of, or afflicted with, the indication an effective amount of a peptide comprising no more than 30 amino acid residues, which peptide comprises SEQ ID NO:1, SEQ ID NO:7, SEQ ID NO:38, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:65, SEQ ID NO:66, SEQ ID NO:67, SEQ ID NO:68, SEQ ID NO:72, SEQ ID NO:73, ~~or~~ SEQ ID NO:74, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:27, reverse D Glu-Ile-Cys-Leu-Asp-Pro-Lys-Gln-Lys-Trp-Ile-Gln, reverse D Glu-Ile-Cys-Leu-Asp-Pro-Lys-Gln-Lys-Trp-Ile-Gln-Cys, or reverse D Glu-Ile-Cys-Ala-Asp-Pro-Lys-Gln-Lys-Trp-Val-Gln-Cys.

69. (Currently amended) A method ~~to modulate the chemokine-induced activity of~~ preventing or inhibiting hematopoietic ~~cells~~ cell recruitment at a preselected physiological site, comprising: administering to a mammal a dosage form comprising an effective amount of a peptide comprising no more than 30 amino acid residues, which peptide comprises SEQ ID NO:1, SEQ ID NO:7, SEQ ID NO:38, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:65, SEQ ID NO:66, SEQ ID NO:67, SEQ ID NO:68, SEQ ID NO:72, SEQ ID NO:73, ~~or~~ SEQ ID NO:74, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:27, reverse D Glu-Ile-Cys-Leu-Asp-Pro-Lys-Gln-Lys-Trp-Ile-Gln, reverse D Glu-Ile-Cys-Leu-Asp-Pro-Lys-Gln-Lys-Trp-Ile-Gln-Cys, or reverse D Glu-Ile-Cys-Ala-Asp-Pro-Lys-Gln-Lys-Trp-Val-Gln-Cys, wherein the dosage form is linked to a site targeting moiety.

70. (Canceled)

71. (Currently amended) A method of preventing or inhibiting an indication associated with a ~~chemokine-induced activity~~ leukocyte migration, comprising: administering to a mammal afflicted with, or at risk of, the indication an effective amount of CRD-Cys-Leu-Asp-Pro-Lys-Gln-Lys-Trp-Ile-Gln-Cys.

72. (Previously presented) A method of preventing or inhibiting an indication associated with hematopoietic cell recruitment, comprising: administering to a mammal at risk of, or afflicted with, the indication an effective amount of CRD-Cys-Leu-Asp-Pro-Lys-Gln-Lys-Trp-Ile-Gln-Cys.

73. (Currently amended) A method ~~to modulate the chemokine-induced activity of preventing or inhibiting hematopoietic cells~~ cell recruitment at a preselected physiological site, comprising: administering to a mammal a dosage form comprising an effective amount of CRD-Cys-Leu-Asp-Pro-Lys-Gln-Lys-Trp-Ile-Gln-Cys, wherein the dosage form is linked to a site targeting moiety.

74. (Canceled)

75. (Currently amended) A method of inhibiting an indication associated with ~~a chemokine-induced activity~~ leukocyte recruitment, comprising: administering to a mammal afflicted with the indication an effective amount of Glu-Ile-Cys-Leu-Asp-Pro-Lys-Gln-Lys-Trp-Ile-Gln (SEQ ID NO:14).

76. (Previously presented) A method of inhibiting an indication associated with hematopoietic cell recruitment, comprising: administering to a mammal afflicted with the indication an effective amount of Glu-Ile-Cys-Leu-Asp-Pro-Lys-Gln-Lys-Trp-Ile-Gln (SEQ ID NO:14).

77. (Currently amended) A method of inhibiting ~~chemokine-induced activity of hematopoietic cells~~ cell recruitment at a preselected physiological site, comprising: administering to a mammal a dosage form comprising an effective amount of Glu-Ile-Cys-Leu-Asp-Pro-Lys-Gln-Lys-Trp-Ile-Gln (SEQ ID NO:14), wherein the dosage form is linked to a site targeting moiety.

78. (Currently amended) A method of inhibiting an indication associated with ~~a chemokine-induced activity~~ leukocyte migration, comprising: administering to a mammal afflicted with the indication an effective amount of a peptide comprising no more than 30 amino acid residues,

which peptide comprises SEQ ID NO:1, SEQ ID NO:7, SEQ ID NO:38, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:65, SEQ ID NO:66, SEQ ID NO:67, SEQ ID NO:68, SEQ ID NO:72, SEQ ID NO:73, or SEQ ID NO:74.

79. (Previously presented) A method of inhibiting an indication associated with hematopoietic cell recruitment, comprising: administering to a mammal afflicted with the indication an effective amount of a peptide comprising no more than 30 amino acid residues, which peptide comprises SEQ ID NO:1, SEQ ID NO:7, SEQ ID NO:38, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:65, SEQ ID NO:66, SEQ ID NO:67, SEQ ID NO:68, SEQ ID NO:72, SEQ ID NO:73, or SEQ ID NO:74.

80. (Currently amended) A method of inhibiting ~~chemokine-induced activity of~~ hematopoietic cells cell recruitment at a preselected physiological site, comprising: administering to a mammal a dosage form comprising an effective amount of a peptide comprising no more than 30 amino acid residues, which peptide comprises SEQ ID NO:1, SEQ ID NO:7, SEQ ID NO:38, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:65, SEQ ID NO:66, SEQ ID NO:67, SEQ ID NO:68, SEQ ID NO:72, SEQ ID NO:73, or SEQ ID NO:74, wherein the dosage form is linked to a site targeting moiety.

81. (Currently amended) A method of inhibiting an indication associated with a ~~chemokine-induced activity~~ leukocyte migration, comprising: administering to a mammal afflicted with the indication an effective amount of CRD-Cys-Leu-Asp-Pro-Lys-Gln-Lys-Trp-Ile-Gln-Cys.

82. (Previously presented) A method of inhibiting an indication associated with hematopoietic cell recruitment, comprising: administering to a mammal afflicted with the indication an effective amount of CRD-Cys-Leu-Asp-Pro-Lys-Gln-Lys-Trp-Ile-Gln-Cys.

83. (Currently amended) A method of inhibiting ~~chemokine-induced activity of~~ hematopoietic cells cell recruitment at a preselected physiological site, comprising: administering to a mammal

AMENDMENT AND RESPONSE UNDER 37 CFR § 1.116 – EXPEDITED PROCEDURE

Serial Number: 09/150813

Filing Date: September 11, 1998

Title: COMPOUNDS AND METHODS TO INHIBIT OR AUGMENT AN INFLAMMATORY RESPONSE

Page 6

Dkt: 1543.002US1

a dosage form comprising an effective amount of CRD-Cys-Leu-Asp-Pro-Lys-Gln-Lys-Trp-Ile-Gln-Cys, wherein the dosage form is linked to a site targeting moiety.